J B CHEMICALS AND PHARMA

JB Chemicals & Pharmaceuticals Limited has submitted to the Exchange a copy of the Minutes of Annual General Meeting (AGM) of the Company held on August 14, 2013.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange outcome of Annual General Meeting held on August 14, 2013 pursuant to clause 35A of the Listing Agreement.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on July 26, 2013, has approved proposal of marketing of the products in Russia-CIS region by a subsidiary of the Company in Dubai, which is hitherto undertaken by the Company. This proposal is expected to become operational during this year.

JB Chemicals & Pharmaceuticals Limited has submitted to the Exchange the Standalone Financial Results along with the Limited Review Report for the period ended June 30,2013.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding a press release dated July 26, 2013 in respect of the unaudited financial results for the quarter ended on June 30, 2013.

JB Chemicals & Pharmaceuticals Limited has submitted to the Exchange a copy of the Notice of the Annual General Meeting of the Members of the company to be held on August 14, 2013.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange that the Company has fixed Book Closure from August 3, 2013 to August 14, 2013 for the purpose of Annual General Meeting and Declaration of dividend. Further the Annual General Meeting of the Company to be held on August 14, 2013.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange that With reference to the earlier announcement dated October 11, 2012 about receipt of notices of claim from Cilag GmbH International and Johnson & Johnson LLC entities under transaction documents in relation to sale of Russia-CIS OTC business, corresponding to the amount held in the Escrow Account & also reference to the earlier announcement dated February 11, 2013 informing about release of Rs. 25.24 crores to the Company from the Escrow Account. The Company has now informed the Exchange that Cilag GmbH International, Johnson

JB Chemicals & Pharmaceuticals Limited has informed the Exchange that the compensation committee of the board of directors of the company has, on June 07, 2013, issued and allotted 4,500 equity shares of face value of Rs. 2 each at a premium of Rs. 61 per share to an employee against the exercise of options granted to them pursuant to Employees Stock Option Scheme of the company. The issued and paid up capital has thus gone up from 8,47,07,300 equity shares of Rs. 2 each to 8,47,11,800 equity shares of Rs. 2 each.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on May 24, 2013 has recommended dividend @ Rs.3.00 (150%) per equity share of face value of Rs.2/-, for the financial year ended 2012-13. This together with dividend tax would absorb Rs.2973.10 lacs.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange that the dividend if declared, will be paid/despatched on August 23, 2013.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 24, 2013, titled "Revenue Growth:19%-PBT(before exceptional item) Growth:122%, Audited Financial Results for the year 2012-13"

JB Chemicals & Pharmaceuticals Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended March 31,2013.

Jyotindra Mody Holdings Pvt ltd has submitted to the Exchange vide its letter dated May 13, 2013 a Copy of Disclosures under Regulation 10(6) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange that Dr. Rajen D. Shah has resigned from the board of directors of the Company w.e.f. April 15, 2013.

JB Chemicals & Pharmaceuticals Limited had informed the Exchange regarding the closure of the sale of Russia-CIS OTC business undertaking to Cilag GmbH International, a subsidiary of Johnson & Johnson, and the receipt of part consideration, and the balance being kept in the agreed Escrow Account. The Company also refer to letter dated October 11, 2012 informing the exchange about the receipt of claim from Johnson & Johnson group entities corresponding to the amount held in the Escrow Account. The Company would now like to inform that an amount of Rs. 25.24 crores has been released to the compa

JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding a press release dated February 05, 2013, titled "Unaudited Financial Results for Q3 - 2012-13".

JB Chemicals & Pharmaceuticals Limited has submitted to the Exchange the Standalone Financial Results for the period ended December 31,2012.

Dinesh Mody Securities Private Limited has submitted to the Exchange vide letter dated November 26, 2012 a copy of Disclosure in terms of Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 along with Regulation 13(4A) of SEBI (Prohibition of Insider Trading) Regulations, 1992.

Kumud Mody Securities Pvt. Ltd. has submitted to the Exchange vide letter dated November 26, 2012 a copy of Disclosure in terms of Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 along with Regulation 13(4A) of SEBI (Prohibition of Insider Trading) Regulations, 1992.

Jyotindra Mody Holdings Pvt. Ltd. has submitted to the Exchange vide letter dated November 26, 2012 a copy of disclosure in terms of Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 along with a copy of disclosure in terms of Regulation 13(4A) of SEBI (Prohibition of Insider Trading) Regulations, 1992.

Unique Pharmaceutical Laboratories Limited has submitted to the Exchange vide letter dated November 26, 2012 a copy of Disclosure in terms of Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 along with Regulation 13(4A) of SEBI (Prohibition of Insider Trading) Regulations, 1992.

Shirish B. Mody Investment Pvt. Limited has submitted to the Exchange vide letter dated November 26, 2012 a copy of Disclosure in terms of Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 along with Regulation 13(4A) of SEBI (Prohibition of Insider Trading) Regulations, 1992.

Ansuya Mody Securities Pvt. Ltd. has submitted to the Exchange vide letter dated November 26, 2012 a copy of Disclosure in terms of Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 along with Regulation 13(4A) of SEBI (Prohibition of Insider Trading) Regulations, 1992.

Ifiunik Pharmaceuticals Limited has submitted to the Exchange vide letter dated November 26, 2012 a copy of Disclosure in terms of Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 along with Regulation 13(4A) of SEBI (Prohibition of Insider Trading) Regulations, 1992.

Bharati S. Mody Investments Pvt. Ltd. has submitted to the Exchange vide letter dated November 26, 2012 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Jyotindra Mody Holdings Pvt. Ltd., Ansuya Mody Securities Pvt. Ltd., Dinesh Mody Securities Pvt. Ltd., Kumud Mody Securities Pvt. Ltd., Shirish B. Mody Investments Pvt. Ltd., Bharati S. Mody Investments Pvt. Ltd. has submitted to the Exchange vide letter dated November 15, 2012 a copy of disclosure under Regulation 10(5) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Jb Chemicals & Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 01, 2012, titled "Unaudited Financial Results for Q2-2012-13."

JB Chemicals & Pharmaceuticals Limited has submitted to the Exchange the Standalone Financial Results for the period ended September 30,2012.

Jb Chemicals & Pharmaceuticals Limited has informed the Exchange that with reference to the Company's earlier communication dated May 23, 2011 informing the Exchange about the company's sale of Russia-CIS OTC business undertaking to Cilag GmbH International, Switzerland, ('Cilag'), a subsidiary of Johnson & Johnson, and communication dated July 14, 2011 informing the Exchange about the closure of the said transaction and the receipt part from the consideration, the balance being kept in the agreed Escrow Account. The Company and its subsidiary have received claims by the Johnson & Johnson grou

Jb Chemicals & Pharmaceuticals Limited has submitted to the Exchange a copy of the minutes of the Annual General Meeting of the members of the Company held on July 30, 2012.

Jb Chemicals & Pharmaceuticals Limited has informed the Exchange regarding a press release dated August 06, 2012, titled "Unaudited Financial Results for Q1-2012-13."

JB Chemicals & Pharmaceuticals Limited has submitted to the Exchange the Standalone Financial Results for the period ended June 30,2012.

Jb Chemicals & Pharmaceuticals Limited has informed the Exchange regarding the Outcome of the Annual General Meeting of the Company held on July 30, 2012.

Jb Chemicals & Pharmaceuticals Limited has informed the Exchange that the Company has decided to close the Register of Member and Share Transfer Books from July 21, 2012 to July 30, 2012 (both days inclusive) for the purpose of Annual General Meeting and Declaration of Dividend.

Jb Chemicals & Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 23, 2012, titled "Audited Financial Results for the year 2011-12."

Jb Chemicals & Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on May 23, 2012 has recommended final dividend @ Re. 1.00 (50%) per equity share of face value of Rs.2/-, for the financial year ended 2011-12. This together with dividend tax would absorb Rs. 984.49lacs. The dividend if declared, will be paid/ despatched on August 9, 2012.

JB Chemicals & Pharmaceuticals Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended March 31,2012.

Jb Chemicals & Pharmaceuticals Limited has informed the Exchange that the board of directors at its meeting held on April 18, 2012, has appointed Mr. Jashvantrai B. Joshi as a director of the company in casual vacancy. He is an independent director on board of the company. Further, the Company has informed the Exchange that the board of directors at the said meeting, has appointed Mr. Sanjay Asher as an alternate director to Mr. Jashvantrai B. Joshi.

Jb Chemicals & Pharmaceuticals Limited has informed the Exchange that Mr. Rohan Shah has resigned from the board of directors of the company w.e.f. March 05, 2012.

Jb Chemicals & Pharmaceuticals Limited has informed the Exchange regarding a press release dated January 25, 2012, titled "J.B.Chemicals: Financial Results for Q3 2011-12."

JB Chemicals & Pharmaceuticals Limited has submitted to the Exchange the Standalone Financial Results for the period ended December 31,2011.

Jb Chemicals & Pharmaceuticals Limited has informed the Exchange that the compensation committee of the board of directors of the company has, on November 28, 2011, issued and allotted 2,500 equity shares of face value of Rs. 2 each at a premium of Rs. 61 per share to an employee against the exercise of options granted to him pursuant to Employees Stock Option Scheme of the company. The issued and paid up capital has thus gone up from 8,47,04,800 equity shares of Rs. 2 each to 8,47,07,300 equity shares of Rs. 2 each.

Jb Chemicals & Pharmaceuticals Limited has informed the Exchange regarding a press release dated October 19, 2011, titled "J.B.Chemicals: Financial Results for Q2 2011-12."

JB Chemicals & Pharmaceuticals Limited has submitted to the Exchange the Standalone Financial Results for the period ended September 30,2011.

Jb Chemicals & Pharmaceuticals Limited has informed the Exchange regarding a press release dated September 26, 2011 that the company plans to issue in connection with mutual calling off of the proposed prescription products deal between the company and Dr. Reddy's Laboratories Limited ("DRL") that involved sale of the company's Russia-CIS prescription products business to DRL.

Jb Chemicals & Pharmaceuticals Limited had informed the Exchange regarding the Company's decision to sell certain of its Russia-CIS prescription products business to Dr. Reddy's Laboratories Limited, Hyderabad (Dr. Reddy's) ("the Proposed Deal"). Further, the Company has now informed the Exchange that the Company as well as Dr. Reddy's have agreed with immediate effect not to pursue the Proposed Deal in their overall business interests. Accordingly, the Proposed Deal has been mutually called off. Consequently, the Company's subsidiary situated in Russia and Dr. Reddy's Russian subsidiary have

Jb Chemicals & Pharmaceuticals Limited has submitted to the Exchange a copy of the minutes of the Annual General Meeting of the members of the Company held on July 25, 2011.

Jb Chemicals & Pharmaceuticals Limited has informed the Exchange regarding outcome of voting by postal ballot.

Jb Chemicals & Pharmaceuticals Limited has informed the Exchange that the special interim dividend declared by the board of directors on August 19, 2011 will be paid/ dispatched on September 09, 2011.